Small-molecule enhancers of autophagy modulate cellular disease phenotypes suggested by human genetics

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 31, 2015, Pages E4281-E4287

  Kuo, Szu Yu ^a,b   Castoreno, Adam B ^a,i   Aldrich, Leslie N ^a,c,j   Lassen, Kara G ^a,d   Goel, Gautam ^a,d   Dančík, Vlado ^a   Kuballa, Petric ^a,d,k   Latorre, Isabel ^a   Conway, Kara L ^a,d   Sarkar, Sovan ^e,f   Maetzel, Dorothea ^e   Jaenisch, Rudolf ^e,g   Clemons, Paul A ^a   Schreiber, Stuart L ^a,c,h   Shamji, Alykhan F ^a   Xavier, Ramnik J ^a,d  

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b HARVARD UNIVERSITY   (United States)

^c HARVARD UNIVERSITY   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^g SKOLKOVO INSTITUTE OF SCIENCE AND TECHNOLOGY   (Russian Federation)

^h HOWARD HUGHES MEDICAL INSTITUTE   (United States)

ⁱ ALNYLAM PHARMACEUTICALS   (United States)

^j UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^k ROCHE DIAGNOSTICS GMBH   (Germany)

more..

Author keywords

Autophagy; Crohn's disease; High throughput screening; Small molecule probes

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; BRD 5631; IMMUNOMODULATING AGENT; UNCLASSIFIED DRUG; CARRIER PROTEIN; ENHANCED GREEN FLUORESCENT PROTEIN; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 1BETA; MEMBRANE PROTEIN; MOLECULAR LIBRARY; NPC1 PROTEIN, HUMAN; PEPTIDE; POLYGLUTAMINE;

ARTICLE; AUTOPHAGY; BACTERIAL REPRODUCTION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENHANCER REGION; FEMALE; HELA CELL LINE; HUMAN; HUMAN CELL; MOLECULAR PATHOLOGY; MOLECULAR PROBE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN AGGREGATION; BACTERIUM; BIOLOGICAL MODEL; CELL AGGREGATION; CHEMISTRY; DRUG EFFECTS; GENETICS; HIGH THROUGHPUT SCREENING; MEDICAL GENETICS; METABOLISM; MOLECULAR LIBRARY; NERVE CELL; NIEMANN PICK DISEASE; PATHOLOGY; PHARMACOLOGY; PLURIPOTENT STEM CELL; SECRETION (PROCESS);

BACTERIA (MICROORGANISMS);

AUTOPHAGY; BACTERIA; CARRIER PROTEINS; CELL AGGREGATION; GENETICS, MEDICAL; GREEN FLUORESCENT PROTEINS; HELA CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; INTERLEUKIN-1BETA; MEMBRANE GLYCOPROTEINS; MODELS, BIOLOGICAL; NEURONS; NIEMANN-PICK DISEASE, TYPE C; PEPTIDES; PHENOTYPE; SMALL MOLECULE LIBRARIES;

EID: 84938634768     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1512289112     Document Type: Article

References (48)

1. Rubinsztein DC, Codogno P, Levine B (2012) Autophagy modulation as a potential therapeutic target for diverse diseases. Nat Rev Drug Discov 11(9):709-730.
2. Feng Y, He D, Yao Z, Klionsky DJ (2014) The machinery of macroautophagy. Cell Res 24(1):24-41.
3. Stolz A, Ernst A, Dikic I (2014) Cargo recognition and trafficking in selective autophagy. Nat Cell Biol 16(6):495-501.
4. Kuballa P, Nolte WM, Castoreno AB, Xavier RJ (2012) Autophagy and the immune system. Annu Rev Immunol 30:611-646.
5. Lassen KG, et al. (2014) Atg16L1 T300A variant decreases selective autophagy resulting in altered cytokine signaling and decreased antibacterial defense. Proc Natl Acad Sci USA 111(21):7741-7746.
6. Cadwell K, et al. (2008) A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 456(7219):259-263.
7. Saitsu H, et al. (2013) De novo mutations in the autophagy gene WDR45 cause static encephalopathy of childhood with neurodegeneration in adulthood. Nat Genet 45(4): 445-449, 449e1.
8. Oz-Levi D, et al. (2012) Mutation in TECPR2 reveals a role for autophagy in hereditary spastic paraparesis. Am J Hum Genet 91(6):1065-1072.
9. Akizu N, et al. (2015) Biallelic mutations in SNX14 cause a syndromic form of cerebellar atrophy and lysosome-autophagosome dysfunction. Nat Genet 47(5):528-534.
10. Cheng Y, Ren X, Hait WN, Yang JM (2013) Therapeutic targeting of autophagy in disease: Biology and pharmacology. Pharmacol Rev 65(4):1162-1197.
11. Shaw SY, et al. (2013) Selective modulation of autophagy, innate immunity, and adaptive immunity by small molecules. ACS Chem Biol 8(12):2724-2733.
12. Kim JJ, et al. (2012) Host cell autophagy activated by antibiotics is required for their effective antimycobacterial drug action. Cell Host Microbe 11(5):457-468.
13. Sundaramurthy V, et al. (2013) Integration of chemical and RNAi multiparametric profiles identifies triggers of intracellular mycobacterial killing. Cell Host Microbe 13(2):129-142.
14. Shoji-Kawata S, et al. (2013) Identification of a candidate therapeutic autophagyinducing peptide. Nature 494(7436):201-206.
15. Hidvegi T, et al. (2010) An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. Science 329(5988): 229-232.
16. Sarkar S (2013) Regulation of autophagy by mTOR-dependent and mTORindependent pathways: Autophagy dysfunction in neurodegenerative diseases and therapeutic application of autophagy enhancers. Biochem Soc Trans 41(5):1103-1130.
17. Sarkar S, et al. (2013) Impaired autophagy in the lipid-storage disorder Niemann-Pick type C1 disease. Cell Reports 5(5):1302-1315.
18. Maetzel D, et al. (2014) Genetic and chemical correction of cholesterol accumulation and impaired autophagy in hepatic and neural cells derived from Niemann-Pick Type C patient-specific iPS cells. Stem Cell Rep 2(6):866-880.
19. Chiu HC, et al. (2009) Eradication of intracellular Salmonella enterica serovar Typhimurium with a small-molecule, host cell-directed agent. Antimicrob Agents Chemother 53(12):5236-5244.
20. Tattoli I, et al. (2012) Amino acid starvation induced by invasive bacterial pathogens triggers an innate host defense program. Cell Host Microbe 11(6):563-575.
21. Harris J, et al. (2011) Autophagy controls IL-1beta secretion by targeting pro-IL-1beta for degradation. J Biol Chem 286(11):9587-9597.
22. Motzer RJ, et al.; RECORD-1 Study Group (2008) Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449-456.
23. Nielsen TE, Schreiber SL (2008) Towards the optimal screening collection: a synthesis strategy. Angew Chem Int Ed Engl 47(1):48-56.
24. Marcaurelle LA, et al. (2010) An aldol-based build/couple/pair strategy for the synthesis of medium- and large-sized rings: Discovery of macrocyclic histone deacetylase inhibitors. J Am Chem Soc 132(47):16962-16976.
25. Gerard B, et al. (2011) Synthesis of a stereochemically diverse library of medium-sized lactams and sultams via S(N)Ar cycloetherification. ACS Comb Sci 13(4):365-374.
26. Fitzgerald ME, et al. (2012) Build/couple/pair strategy for the synthesis of stereochemically diverse macrolactams via head-to-tail cyclization. ACS Comb Sci 14(2): 89-96.
27. Kabeya Y, et al. (2000) LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 19(21):5720-5728.
28. Kimura S, Noda T, Yoshimori T (2007) Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy 3(5): 452-460.
29. Nadanaciva S, et al. (2011) A high content screening assay for identifying lysosomotropic compounds. Toxicol In Vitro 25(3):715-723.
30. Ashoor R, Yafawi R, Jessen B, Lu S (2013) The contribution of lysosomotropism to autophagy perturbation. PLoS One 8(11):e82481.
31. Vázquez CL, Colombo MI (2009) Assays to assess autophagy induction and fusion of autophagic vacuoles with a degradative compartment, using monodansylcadaverine (MDC) and DQ-BSA. Methods Enzymol 452:85-95.
32. Lemieux B, Percival MD, Falgueyret JP (2004) Quantitation of the lysosomotropic character of cationic amphiphilic drugs using the fluorescent basic amine Red DND-99. Anal Biochem 327(2):247-251.
33. Thoreen CC, et al. (2009) An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 284(12): 8023-8032.
34. Kim J, Kundu M, Viollet B, Guan KL (2011) AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 13(2):132-141.
35. Balgi AD, et al. (2009) Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PLoS One 4(9):e7124.
36. Ravikumar B, et al. (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 36(6):585-595.
37. Sarkar S, Ravikumar B, Rubinsztein DC (2009) Autophagic clearance of aggregateprone proteins associated with neurodegeneration. Methods Enzymol 453:83-110.
38. Bjørkøy G, et al. (2005) p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol 171(4): 603-614.
39. Sahani MH, Itakura E, Mizushima N (2014) Expression of the autophagy substrate SQSTM1/p62 is restored during prolonged starvation depending on transcriptional upregulation and autophagy-derived amino acids. Autophagy 10(3):431-441.
40. Huang J, Brumell JH (2014) Bacteria-autophagy interplay: A battle for survival. Nat Rev Microbiol 12(2):101-114.
41. Conway KL, et al. (2013) Atg16l1 is required for autophagy in intestinal epithelial cells and protection of mice from Salmonella infection. Gastroenterology 145(6): 1347-1357.
42. Cong L, et al. (2013) Multiplex genome engineering using CRISPR/Cas systems. Science 339(6121):819-823.
43. Fujita N, et al. (2008) The Atg16L complex specifies the site of LC3 lipidation for membrane biogenesis in autophagy. Mol Biol Cell 19(5):2092-2100.
44. Kuballa P, Huett A, Rioux JD, Daly MJ, Xavier RJ (2008) Impaired autophagy of an intracellular pathogen induced by a Crohn's disease associated ATG16L1 variant. PLoS One 3(10):e3391.
45. Plantinga TS, et al. (2011) Crohn's disease-associated ATG16L1 polymorphism modulates pro-inflammatory cytokine responses selectively upon activation of NOD2. Gut 60(9):1229-1235.
46. Kaufmann AM, Krise JP (2007) Lysosomal sequestration of amine-containing drugs: Analysis and therapeutic implications. J Pharm Sci 96(4):729-746.
47. Kornhuber J, et al. (2011) Identification of novel functional inhibitors of acid sphingomyelinase. PLoS One 6(8):e23852.
48. Halliwell WH (1997) Cationic amphiphilic drug-induced phospholipidosis. Toxicol Pathol 25(1):53-60.